New anti-cancer agent disrupts blood flow to tumors, starving them but sparing healthy cells
April 15, 2008
The Institute for Drug Development, a division of The Cancer Therapy & Research Center at The University of Texas Health Science Center at San Antonio, announced the results of a new phase I clinical study on NPI-2358, a targeted anti-cancer agent designed to rapidly disrupt blood flow to the tumor mass, causing tumor death.